Mostrando 7 resultados de: 7
Filtros aplicados
Origen
scopus(7)
1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients
ArticleAbstract: Conventional treatment of non-small cell lung cancer (NSCLC) has apparently reached a plateau of effPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Aguirre F., Alfonso S., Alonso D.F., Barroso M.C., Carmen Elena Viada, De La Torre A.V., Díaz R.M., Gabri M.R., Gómez R., Hernández A.M., Macías A.E., Pérez K., Pérez R., Rodríguez J., Santiesteban E.R., Suárez E., Toledo D., Vázquez A.M.Fuentes:scopusCIMAvax-EGF: Toward long-term survival of advanced NSCLC
ReviewAbstract: Lung cancer remains one of the leading causes of cancer-related deaths. Non–small cell lung cancer (Palabras claves:cancer vaccine, CIMAvax-EGF, Clinical trial, EGF, Epidermal growth factor receptor, immunotherapy, non–small cell lung cancerAutores:Camilo Rodríguez, Carmen Elena Viada, Lage Davila A., Mazorra Z., Neninger Vinageras E., Saavedra Hernández D., Tania CrombetFuentes:scopusEvaluation of CIMAvaxEGF for the treatment of lung cancer: Meta-analysis of controlled clinical trials
ArticleAbstract: CIMAvaxEGF is a therapeutic cancer vaccine developed in Cuba and fully licensed in the country for uPalabras claves:EGF receptor, Epidermal growth factor, immunotherapy, Of non-small cell lung cancer vaccine therapy, Oncology vaccinesAutores:Aliuska Frías, Ballesteros J., Bárbara Wilkinson, Camilo Rodríguez, Carmen Elena Viada, Mabel Álvarez, Martha M. Fors-López, Neninger Vinageras E., Quintero J., Robaina M., Tania CrombetFuentes:scopusEvaluation of racotumomab for the treatment of lung cancer: Meta-analysis of controlled trials of the CIM
ArticleAbstract: Racotumomab is a therapeutic cancer vaccine entirely developed in Cuba and licensed in the country fPalabras claves:immunotherapy, Non-small cell lung cancer, Oncological vaccines, Racotumomab, Vaccinal treatmentAutores:Alfonso S., Aliuska Frías, Ballesteros J., Carmen Elena Viada, Hernández M., Mabel Álvarez, Macías A.E., Martha M. Fors-López, Quintero J., Robaina M.Fuentes:scopusDifferential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer
ArticleAbstract: Background: Progress in immunotherapy has revolutionized the treatment landscape for advanced lung cPalabras claves:immunotherapy, long-term survival, non–small cell lung cancer, survival mixture modelsAutores:Alfonso S., Carmen Elena Viada, Lage Davila A., Luaces P.L.o., Muchene L., Neninger Vinageras E., Rodríguez P.C., Sánchez L., Shkedy Z., Tania CrombetFuentes:scopusNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopusImmunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients
ArticleAbstract: Increased levels of NeuGc-containing gangliosides have been described in human breast cancer. A contPalabras claves:Breast Cancer, cancer vaccine, Clinical trial, Ganglioside, immunotherapy, NeuGcGM3, patientsAutores:Cardoso J., Carmen Elena Viada, Carr A., De La Torre A.V., Díaz R., Fernandez L.E., Macías A.E., Marinello P., Mazorra Z., Mulens V., O'Farrill M., Pérez R., Rodríguez R., Saurez G., Tania CrombetFuentes:scopus